Multicenter prospective Study to determine the efficacy of Strontium-89 for palliation of painful bone metastases in cancer patients

Multicenter prospective Study to determine the efficacy of Strontium-89 for palliation of painful bone metastases in cancer patients - PMS-89

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000004028

Enrollment

200

Registered

2010-08-10

Start date

2010-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

painful bone metastases

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Histologically/cytologically proven solid tumor 2) Multiple bone metastases consisted with positive site of bone scintigram 3) Baseline pain score was 3 or more. 4) Patient was obtained insufficient effect by analgesics 5) Patient can not adapt to EBRT 6) Life expectancy>=1 month 7) Adequate haematological function: - Haemoglobin>=9g/dl - WBC count>=3,000/mm3 - Platelets>=75,000/mm3 8) Written informed consent

Exclusion criteria

Exclusion criteria: 1) severe myelosupppression 2) marked fall of hematological function 3) Administration of Sr-89 within previous 3 months 4) DIC 5) Severe renal disfunction 6) Multiple myeloma 7) Pregnancy 8) Any condition, which, in the opinion of the investigator, might interfere with the evaluation of the study objectives

Design outcomes

Primary

Measure	Time frame
Response rate of palliative efficacy based on pain score recorded by patients	—

Secondary

Measure	Time frame
Prognostic factor of palliative effect QOL Safety	—

Countries

Japan

Contacts

Public ContactMakoto Hosono

Kindai University Hospital Institute of Advanced Clinical Medicine

hosono@med.kindai.ac.jp072-366-0221

Outcome results